Refine
Document Type
- Article (4)
- Doctoral Thesis (1)
Language
- English (5)
Has Fulltext
- yes (5)
Is part of the Bibliography
- no (5)
Keywords
- SARS-CoV-2 (1)
- animal experiments (1)
- basement membrane (1)
- blood–brain barrier (1)
- crosslinking (1)
- electrospinning (1)
- extracellular matrix (1)
- gelatin (1)
- human induced pluripotent stem cells (1)
- in vitro model (1)
Institute
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.
Electrospinning is an advanced method for the generation of polymer-based fibers. This fabrication technique has gained great interest in the biomedical field in recent years due to its straightforward application and significant versatility of the resulting fiber mats. The process is carried out by dissolving a (biologically or synthetically derived) polymer or a combination of several polymers in a suitable inorganic or organic solvent and transferring these solutions into a syringe with a needle tip as a spinneret. The power source is connected to the syringe tip, allowing for the application of a high voltage to the polymer solution, and a metallic collector, often a rotating drum cylinder on which the yielded polymer fibers are deposited. The usual fiber diameters range between nano- and micrometers. The yielded fiber mats have distinct characteristics, such as a large surface area, mechanical stability, and good encapsulation efficiency. Therefore, the fiber mats can be used as a topical dosage form for a multitude of diseases (e.g., conjunctivitis, keratitis), as they can be easily applied on or into the human body to release the drug for a prolonged period of time. In addition, the fibers exhibit a high degree of resemblance with the human extracellular matrix, which consists predominantly of collagen fibrils. Therefore, the obtained fiber mats can also be employed as innovative substrates for the cultivation of cells. As a result, electrospinning is suitable for a wide range of applications in the biomedical context, specifically for the targeted, topical delivery of bioactives and also as a cell culture substrate for the cultivation of cells in an enhanced in vivo relevant situation.
One objective of this work was the development and characterization of drug-loaded electrospun fibers for application to the inflamed and infected eye to complement the existing therapy of eye drops as well as systemic administration of anti-infectives. In particular, the focus of the project was the development of ocular implants to treat a herpes simplex infection affecting the human cornea. Additionally, electrospun fibers, which immediately dissolve in the tear fluid upon application and prolong the contact time of the bioactives at the eye, were developed as a topical dosage form to treat bacterial conjunctivitis. An additional objective of this work was the development of electrospun fiber mats as an innovative substrate for the cultivation of human induced pluripotent stem cells to mimic the human blood-brain barrier in vitro. The final objective of the present work was establishing an analytical concept for the comprehensive characterization of electrospun fibers to obtain a greater comparability and reproducibility of data and results from different laboratories.
Herpes simplex keratitis is a viral disease of the cornea that can potentially lead to blindness. This disease commonly occurs after corneal transplantation. As the cornea is the most transplanted tissue worldwide, the incidence of this disease varies from 4.9% to 12.6% (high- and low-income countries). The current therapy involves the application of eye drops as many as six times a day, and in severe cases, the systemic use of antiviral agents is necessary but can cause serious side effects (e.g., renal failure). To prevent the occurrence of herpes simplex keratitis after transplantation, a biodegradable electrospun nanofiber mat with a sustained release of acyclovir was established. The rational development of the fibers was facilitated by correlating the surface wettability with the release kinetics of the individual polymers, which allowed for the successful generation of fiber mats releasing the bioactive acyclovir over three weeks. The molecularly dispersed drug is present as an amorphous solid dispersion within the PLGA-based polymer matrix. Evaluating the cell viability in in vitro models proved that neither acyclovir nor the polymers or the generated fiber mats caused any cytotoxicity. The mechanical stability of the fiber mats was evaluated to ensure adequate handling of the fibers during implantation. The findings demonstrated that the fiber mats exhibit direction-independent mechanical properties, and their mechanical load-bearing capacity is greater than that of an excised human cornea. As a result, the fiber mats are suitable for surgical implantation into the anterior chamber of the eye. An in vitro model of human keratinocytes was infected with herpes simplex virus to demonstrate the antiviral efficacy of the electrospun fiber mats. Immunostaining for two specific viral proteins demonstrated the spread of infection in the model. Hereby, it was found that the placebo- and drug-loaded fibers significantly slowed the spread of infection, which was quantified by plaque assay determination. This experiment revealed that the electrospun fibers exert a synergistic antiviral effect by simultaneously releasing acyclovir, which is a virustatic agent that inhibits the replication of the virus in infected cells, and adsorbing released viral particles onto the surface of the polymer fibers. This reduces the overall burden of released viral particles, which is associated with the severity of the infection outbreak. Thus, with the aid of electrospinning, an ocular implant was successfully generated, which is biodegradable over time and significantly reduces the viral particle burden in vitro. Hence, the fibers represent a potential alternative for the prevention of herpes simplex keratitis after corneal transplantation...
The increasing incidence of infected skin wounds poses a major challenge in clinical practice, especially when conventional antibiotic therapy fails. In this context, bacteriophages emerged as promising alternatives for the treatment of antibiotic-resistant bacteria. However, clinical implementation remains hampered by the lack of efficient delivery approaches to infected wound tissue. In this study, bacteriophage-loaded electrospun fiber mats were successfully developed as next-generation wound dressings for the treatment of infected wounds. We employed a coaxial electrospinning approach, creating fibers with a protective polymer shell, enveloping bacteriophages in the core while maintaining their antimicrobial activity. The novel fibers exhibited a reproducible fiber diameter range and morphology, while the mechanical fiber properties were ideal for application onto wounds. Further, immediate release kinetics for the phages were confirmed as well as the biocompatibility of the fibers with human skin cells. Antimicrobial activity was demonstrated against Staphylococcus aureus and Pseudomonas aeruginosa and the core/shell formulation maintained the bacteriophage activity for 4 weeks when stored at − 20 °C. Based on these promising characteristics, our approach holds great potential as a platform technology for the encapsulation of bioactive bacteriophages to enable the translation of phage therapy into clinical application.
Background: Pulmonary nocardiosis (PN) is an uncommon but potentially life-threatening infection. Most of our knowledge is derived from case reports or smaller case series. Recently, increasing PN incidence rates have been reported. We aim to describe the clinical course of and risk factors for PN in four Western European countries and to estimate population-based annual hospitalization rates.
Methods: Retrospective evaluation (1995 to 2011) of the clinical course of and risk factors for PN in patients from 11 hospitals in four European countries (Germany, Austria, Switzerland and The Netherlands). Calculation of population-based estimates of hospitalization rates of PN in Germany (2005 to 2011) using official German nationwide diagnosis-related groups (DRG) hospital statistics.
Results: Forty-three patients fulfilled stringent criteria for proven (n = 8) and probable (n = 35) PN; seven with extrapulmonary dissemination. Within the 43 patients, major PN risk factors were immunocompromising (83.7%) and/or pulmonary (58.1%; in 27.9% as only comorbidity) comorbidities. Median duration of PN targeted therapy was 12 weeks. Distinguished patterns of resistance were observed (imipenem susceptibility: N. farcinica 33.3%; N. asteroides 66.7%). Overall mortality rate was 18.9%; in disseminated PN 50%. Over time, annual PN hospitalization rates remained unchanged at around 0.04/100′000 with the highest rate among men aged 75–84 years (0.24/100′000).
Conclusion: PN is rare, but potentially life-threatening, and mainly affects immunocompromised elder males. Overall annual hospitalization rates remained stable between 2005 and 2011.
The human blood–brain barrier (BBB) represents the interface of microvasculature and the central nervous system, regulating the transport of nutrients and protecting the brain from external threats. To gain a deeper understanding of (patho)physiological processes affecting the BBB, sophisticated models mimicking the in vivo situation are required. Currently, most in vitro models are cultivated on stiff, semipermeable, and non-biodegradable Transwell® membrane inserts, not adequately mimicking the complexity of the extracellular environment of the native human BBB. To overcome these disadvantages, we developed three-dimensional electrospun scaffolds resembling the natural structure of the human extracellular matrix. The polymer fibers of the scaffold imitate collagen fibrils of the human basement membrane, exhibiting excellent wettability and biomechanical properties, thus facilitating cell adhesion, proliferation, and migration. Cultivation of human induced pluripotent stem cells (hiPSCs) on these scaffolds enabled the development of a physiological BBB phenotype monitored via the formation of tight junctions and validated by the paracellular permeability of sodium fluorescein, further accentuating the non-linearity of TEER and barrier permeability. The novel in vitro model of the BBB forms a tight endothelial barrier, offering a platform to study barrier functions in a (patho)physiologically relevant context.